ÇáãÞÏãÉ
ãÓÊÌÏÇÊ ØÈíÉ
ÕÍÉ ÚÇãÉ
ÇáÃãÑÇÖ ÇáäÓÇÆíÉ
ÃãÑÇÖ ÇáÃØÝÇá
ãæÇÖíÚ ÈÇáÃãÑÇÖ ÇáÏÇÎáíÉ
ÇáËÞÇÝÉ ÇáÌäÓíÉ
ÃãÑÇÖ ãäÊÞáÉ Úä ØÑíÞ ÇáÌäÓ
ÇáÌåÇÒ ÇáÊäÇÓáí ÇáãÄäË Ü ÊÔÑíÍ
ÇáÌåÇÒ ÇáÊäÇÓáí ÇáãÐßÑ
ãÔÇßá ÌäÓíÉ Ü ÑÌÇá
ãÔÇßá ÌäÓíÉ Ü äÓÇÁ
ãæÇÖíÚ ááÃØÈÇÁ æ ØáÇÈ ÇáØÈ
ÞÕÉ ÞÕíÑÉ¡ ÍßÇíÇÊ ØÈíÉ
ÃÞáÇã ÍÑÉ
ÕÝÍÉ ÎÇÕÉ: ÇáÃãÑÇÖ ÇáäÓÇÆíÉ
ÕÝÍÉ ÎÇÕÉ: ÊÚÑÝæÇ Úáì ÇäÝÓßã
ÕÝÍÉ ÎÇÕÉ: Úä ÇáÍãá æ ÇáÌäíä
ÕÝÍÉ ÎÇÕÉ: ÕÍÉ ÚÇãÉ
ÕÝÍÉ ÎÇÕÉ: ËÞÇÝÉ ÌäÓíÉ
ÕÝÍÇÊ ÎÇÕÉ ÈÇáÃØÈÇÁ æ ØáÇÈ ÇáØÈ
ÕÝÍÉ ÎÇÕÉ: ãæÇÖíÚ ÛíÑ ØÈíÉ
ááÞÑÇÁÉ ÞÈá ØÑÍ ÇáÓÄÇá
ãä ÇáÊÑÇË ÇáÚÑÈí
ãÓÊÌÏÇÊ ØÈíÉ - (10) - ÇáÕÝÍÉ ÇáÑÆíÓíÉ - ÇáÕÝÍÉ ÇáÃæáì 2014
ÇáÎÕÇÆÕ ÇáÊí ÇãÊÇÒ ÈåÇ ÇáãÑÖì ÇáÐíä ãÇÊæÇ ÈÝíÑæÓ æÈÇÁ ÇáßæÝíÏ 19 - ßæÑæäÇ Ýí ÇíØÇáíÇ
ÇÚÏÇÏ æÊÑÌãÉ: Ï. áÄí ÎÏÇã æ Ï. ÚãÑ ÝæÒí äÌÇÑí
Characteristics of COVID-19 patients dying in Italy áÎÕÇÆÕ ÇáÊí ÇãÊÇÒ ÈåÇ ÇáãÑÖì ÇáÐíä ãÇÊæÇ ÈÝíÑæÓ æÈÇÁ ÇáßæÝíÏ 19 - ßæÑæäÇ Ýí ÇíØÇáíÇ Report based on available data on March 20th, 2020 íÓÊäÏ ÇáÊÞÑíÑ Åáì ÇáÈíÇäÇÊ ÇáãÊÇÍÉ ÈÊÇÑíÎ 20 ÂÐÇÑ 2020ã 1 sample ÇáÚíäÉ The present report describes characteristics of 3200 COVID-19 patients dying in Italy.* Geographic distribution across the 19 regions and 2 autonomous provinces of Trento and Bozen is presented in the table below. íæÕÝ ÇáÊÞÑíÑ ÇáÎÕÇÆÕ ÇáÊí ãíÒÊ 3200 ãÑíÖ ãÇÊæÇ ÈÝíÑæÓ ßæÑæäÇ Ýí ÇíØÇáíÇ Data are update to March 20th, 2020. ÇáÊæÒÚ ÇáÌÛÑÇÝí: Ôãá 19 ãäØÞÉ æãÞÇØÚÊíä ãÓÊÞáÊíä Ýí ÊÑíäÊæ æ ÈæÒä¡ ßãÇ Ýí ÇáÌÏæá ÃÏäÇå: ÍÇáÇÊ ÇáæÝÇÉ ÇáãÓÌáÉ Ýí ÇáÌÏæá ÃÚáÇå åí ÚäÏ ÇáãÑÖì ÇáÐíä ßÇä ÇÎÊÈÇÑ SARScov-2 RT ÈæÇÓØÉ ÊÞäíÉ ÇáÜ PCR ÅíÌÇÈí ÈÔßá ãÓÊÞá Úä ÇáÃãÑÇÖ ÇáãæÌæÏÉ ÓÇÈÞÇð. 2. ãä ÍíË ÇáÊÑßíÈÉ ÇáÓßÇäíÉ Demographics Mean age of patients dying for COVID-2019 infection was 78.5 (median 80, range 31-103, IQR 73 -85). Women were 942 (29.4%). ßÇä ãÊæÓØ ÚãÑ ÇáãÑÖì ÇáÐíä ãÇÊæÇ ÈÓÈÈ ÇáÚÏæì ÈÝíÑæÓ ÇáßæÝíÏ 19 - ÇáßæÑæäÇ 78¡5ÓäÉ¡ (ÇáæÓØí 80¡ ÊÊÑÇæÍ ÇáÇÚãÇÑ Èíä 31-103¡ ÇáÜ IQR 73-85). ÈáÛ ÚÏÏ ÇáäÓÇÁ 942 ÈäÓÈÉ 29¡4%. Figure 1 shows that median age of patients dying for COVID-2019 infection was more than 15 years higher as compared with the national sample diagnosed with COVID-2019 infection (median age 63 years). íæÖÍ ÇáÔßá ÑÞã 1 Ãä ãÊæÓØ ÚãÑ ÇáãÑÖì ÇáÐíä íãæÊæä ÈÓÈÈ ÇáÚÏæì ÈÝíÑæÓ ÇáßæÑæäÇ ßÇä ÃßËÑ ÈÜ 15 ÓäÉ ãÞÇÑäÉ ãÚ ÇáÚíäÉ ÇáæØäíÉ ÇáÊí Êã ÊÔÎíÕåÇ Úáì ÃäåÇ ãÕÇÈÉ ÈÇáÝíÑæÓ (ÇáÚãÑ ÇáæÓØí 63 ÓäÉ). Figure 1. Median age of patients with COVID-2019 infection and COVID-19 positive deceased patients ÇáÔßá 1 ÇáÚãÑ ÇáãÊæÓØ ááãÑÖì ÇáãÕÇÈíä ÈÇáÚÏæì ÈÝíÑæÓ ÇáßæÑæäÇ COVID-2019 æ COVID-19 ÇáÇíÌÇÈííä ÇáãÊæÝíä. ÊÞÑíÑ ãÌãæÚÉ ãÑÇÞÈÉ COVID-19 ÈíÇäÇÊ ÇíØÇáíÇ Ýí ÇáÜ20 ãä ÂÐÇÑ 2020ã Figure 2 shows the absolute number of deaths by age group. Women dying for COVID-2019 infection had an older age than men (median age women 82 - median age men 79). íæÖÍ ÇáÔßá 2 ÇáÚÏÏ ÇáãØáÞ ááæÝíÇÊ ÍÓÈ ÇáÝÆÉ ÇáÚãÑíÉ¡ ÇáäÓÇÁ ÇááæÇÊí íãÊä ÈÓÈÈ ÇáÚÏæì ÈÇáÜ COVID-2019 ßä ÈÃÚãÇÑ ÃßÈÑ ãä ÇáÑÌÇá (ãÊæÓØ ÃÚãÇÑ ÇáäÓÇÁ 82ÓäÉ¡ ãÊæÓØ ÚãÑ ÇáÑÌÇá 79ÓäÉ). Figure 2. Absolute number of deaths by age group ÇáÔßá 2 íãËá ÇÇáÚÏÏ ÇáãØáÞ ááæÝíÇÊ ÈÍÓÈ ÇáÝÆÉ ÇáÚãÑíÉ 3. ÇáÔÑæØ ÇáãæÌæÏÉ ãÓÈÞÇPre-existing conditions Table 1 presents most common comorbidities diagnosed before COVID-2019 infection. Data on diseases were based on chart review and was available on 481/3200 patients dying in-hospital (15.0% of the sample). Mean number of diseases was 2.7 (median 2, SD 1.6). Overall, 1.2% of the sample presented with a no comorbidities, 23.5% with a single comorbidity, 26.6% with 2, and 48.6% with 3 or more. íÙåÑ ÇáÌÏæá ÑÞã1 ÃßËÑ ÇáÃãÑÇÖ ÇáãÔÎÕÉ ãÓÈÞÇ ÞÈá ÇáÇÕÇÈÉ ÈÇáÝíÑæÓ æÇáÊí ÊÑÇÝÞÊ ãÚ ÇáÚÏæì ÈÝíÑæÓ COVID-2019. æÞÏ ÇÓÊäÏÊ ÇáÈíÇäÇÊ ÇáãÊÚáÞÉ ÈåÐå ÇáÃãÑÇÖ Úáì ãÑÇÌÚÉ ÇáãÎØØÇÊ ÇáÈíÇäíÉ æÇáÊí ßÇäÊ ãÊæÝÑÉ áÜ 481/3200 ãÑíÖ ããä ÊæÝí Ýí ÇáãÔÝì (15% ãä ÇáÚíäÉ) æßÇä ãÊæÓØ ÚÏÏ ÇáÃãÑÇÖ 2¡7 (ÇáãÊæÓØ2 æÇáÇäÍÑÇÝ ÇáãÚíÇÑí 1¡6)¡ æÈÔßá ÚÇã ÝÅäø 1¡2 ãä ÇáÚíäÉ ÇáãÏÑæÓÉ áã Êßä ãÊÑÇÝÞÉ ãÚ ÃãÑÇÖ¡ ÈíäãÇ ÊÑÇÝÞ 23¡5% ãäåÇ ãÚ ãÑÖ æÇÍÏ¡ æ 26¡6% ãäåÇ ãÚ ãÑÖíä æ 48¡6% ãäåÇ ãÚ ËáÇËÉ ÃãÑÇÖ Ãæ ÃßËÑ. ÇáÌÏæá ÑÞã 1 : íáÍÙ ãÚÙã ÇáÃãÑÇÖ ÇáÔÇÆÚÉ ÇáãÑÇÝÞÉ ááÅÕÇÈÉ ÚäÏ ÇáãÑÖì ÇáãÊæÝíä ÇáÅíÌÇÈííä ááÜ COVID-19 Table 1. Most common comorbidities observed in COVID-19 positive deceased patients ÊÞÑíÑ ãÌãæÚÉ ãÑÇÞÈÉ COVID-19 ÈíÇäÇÊ ÇíØÇáíÇ ÈÊÇÑíÎ 20 ÂÐÇÑ 2020ã schemic heart disease % 30.1 Atrial Fibrillation % 22.0 Stroke 54 11.2 Hypertension % 73.8 Diabetes %33.9 Dementia % 11.9 COPD % 13.7 Active cancer in the past 5 years % 19.5 Chronic liver disease % 3.7 Chronic renal failure % 20.2 ÇáÇãÑÇÖ ÇáãÊÑÇÝÞÉ ãÚ ÍÇáÇÊ ÇáæÝíÇÊ ÑÌÝÇä ÃÐíäí 22% ÇáÓßÊÉ ÇáÏãÇÛíÉ 54 11¡2% ÇÑÊÝÇÚ ÖÛØ ÇáÏã 73¡8% ÇáÏÇÁ ÇáÓßÑí 33¡9% ÇáÎÑÝ 11¡9% ÇáÃãÑÇÖ ÇáÊäÝÓíÉ ÇáãÒãäÉ ÇáÍÇÕÑÉ COPD 13¡7% ÓÑØÇä äÔØ ÎáÇá ÇáÓäæÇÊ ÇáÎãÓ ÇáÓÇÈÞÉ ááÅÕÇÈÉ 19¡5% ãÑÖ ßÈÏí ãÒãä 3¡7%. ÝÔá ßáæí ãÒãä 20¡2% 4. ÇáÃÚÑÇÖSymptoms Figure 3 shows symptoms most commonly observed at hospital admission. Fever and dyspnoea were the most commonly observed symptoms, while cough, diarrhoea and haemoptysis were less commonly observed. Overall, 5.7% of patients did not present any symptoms at hospital admission. íÙåÑ ÇáÔßá ÑÞã 3 ÇáÃÚÑÇÖ ÇáÃßËÑ ÔíæÚÇ ÇáãÔÇåÏÉ ÚäÏ ÇáÞÈæá Ýí ÇáãÔÝì ßÇäÊ ÇáÍãì æÖíÞ ÇáäÝÓ ÃßËÑ ÇáÃÚÑÇÖ ÇáãÔÇåÏÉ ÔíæÚÇð. ÈíäãÇ ßÇä ÇáÓÚÇá æÇáÇÓåÇá æäÝË ÇáÏã ÃÞá ãÔÇåÏÉ ÈíäãÇ áã íÙåÑ 5¡7% ãä ÇáãÑÖì Ãí ÚÑÖ æÞÊ ÇáÞÈæá Ýí ÇáãÔÝì íæÖÍ ÇáÔßá 3 ÃßËÑ ÇáÃÚÑÇÖ ÇáãÔÇåÏÉ ÚäÏ ÇáãÑÖì ÇáÅíÌÇÈííä æÇáãÊæÝíä ÈÇáÜ COVID-19. äÝË ÇáÏã ---- áæä ÍÔíÔí ÇÓåÇá ---- áæä ÓãÇæí ÝÇÊÍ ÖíÞ äÝÓ ---- áæä ÈäÝÓÌí ÓÚÇá ---- áæä ÇÍãÑ Íãì ---- áæä ÇÒÑÞ 5. ÍÇáÇÊ ÍÇÏÉAcute conditions Acute Respiratory Distress syndrome was observed in the majority of patients (96.5% of cases), followed by acute renal failure (29.2%). Acute cardiac injury was observed in 10.4% of cases and superinfection in 8.5%. ÔæåÏÊ ãÊáÇÒãÉ ÇáÖÇÆÞÉ ÇáÊäÝÓíÉ ÇáÍÇÏÉ RDS ÚäÏ ÛÇáÈíÉ ÇáãÑÖì 96¡5% ãä ÇáÍÇáÇÊ¡ æíáíåÇ ÇáÝÔá Çáßáæí ÇáÍÇÏ 29¡2% ãä ÇáÍÇáÇÊ¡ ÈíäãÇ ÔæåÏÊ ÇáÃÐíÇÊ ÇáÞáÈíÉ ÇáÍÇÏÉ ÚäÏ 10¡4% ãä ÇáÍÇáÇÊ æÇáÃÎãÇÌ ÇáÝÇÆÞÉ ÚäÏ 8¡5% ãä ÇáÍÇáÇÊ. 6. ÇáÚáÇÌTreatments Antibiotics were used by 84% of patients during hospital stay, while less used were antivirals (54%) and corticosteroids (31%). Concomitant use of these 3 treatments was observed in 18.6% of cases. Before hospitalization, 36% of COVID-19 positive deceased patients followed ACE-inhibitor therapy and 16% angiotensin receptor blockers-ARBs therapy. This information can be underestimated because data on drug treatment before admission were not always described in the chart. ÇÓÊÚãáÊ ÇáãÖÇÏÇÊ ÇáÍíæíÉ ÚäÏ 84% ãä ÇáãÑÖì ÃËäÇÁ ÅÞÇãÊåã Ýí ÇáãÔÝì¡ æßÇä ÇÓÊÚãÇá ãÖÇÏÇÊ ÇáÝíÑæÓÇÊ ÃÞá 54% ÝÞØ æÇáÓÊíÑæÆíÏÇÊ ÚäÏ 31% æÊã ÇÓÊÚãÇá ÇáÃÕäÇÝ ÇáËáÇËÉ ÇáÓÇÈÞÉ ãÚÇ ÚäÏ 18¡6% ãä ÇáÍÇáÇÊ. ÇáÚáÇÌÇÊ ÇáÌÇÑíÉ ÞÈá ÇáÇÓÊÔÝÇÁ ßÇä 36% ãä ÇáãÑÖì ÇáãÊæÝíä ÇáÇíÌÇÈííä ÇáÜ COVID-19 ãÚÇáÌíä ÈãËÈØÇÊ ÇáÂäÒíã ÇáãÍæá ááÇäÌíæÊäÓíä ACE-inhibitor æ 16% ÈÍÇÕÑÇÊ ãÓÊÞÈáÇÊ ÇáÇäÌíæÊäÓíä ARBs ¡ íãßä ÇáÊÞáíá ãä ÃåãíÉ åÐå ÇáãÚáæãÇÊ áÃäå áã íÊã ÏÇÆãÇ æÕÝ ÇáÈíÇäÇÊ ÇáãÊÚáÞÉ ÈÇáÃÏæíÉ ÞÈá ÇáÞÈæá Ýí ÇáãÔÝì . 7. ÇáÎØ ÇáÒãäíTime-line Figure 4 shows, for COVID-19 positive deceased patients, the median times, in days, from the onset of symptoms to death (8 days), from the onset of symptoms to hospitalization (4 days) and from hospitalization to death (4 days). The time from hospitalization to death was 1 day longer in those who were transferred to intensive care than those who were not transferred (5 days vs. 4 days). íæÖÍ ÇáÔßá 4 ÈÇáäÓÈÉ ááãÑÖì ÇáãÊæÝíä ÇáÅíÌÇÈííä ÈÇáäÓÈÉ ááÜ COVID-19¡ ÇáÒãä ÇáæÓØí ÈÇáÃíÇã ãäÐ ÈÏÁ ÇáÃÚÑÇÖ æÍÊì ÇáæÝÇÉ (8ÃíÇã) æãäÐ ÈÏÁ ÇáÃÚÑÇÖ æÍÊì ÇáÇÓÊÔÝÇÁ (4 ÃíÇã) æãäÐ ÇáÇÓÊÔÝÇÁ æÍÊì ÇáæÝÇÉ (4 ÃíÇã) æÞÏ ßÇäÊ ÇáãÏÉ ÇáÒãäíÉ ãÇ Èíä ÇáÇÓÊÔÝÇÁ æÇáæÝÇÉ ÃØæá Èíæã æÇÍÏ ÚäÏ ÃæáÆß ÇáÐíä Êã ÊÍæíáåã Åáì ÇáÚäÇíÉ ÇáãÔÏÏÉ ãÞÇÑäÉ ãÚ ãä áã íÊã ÊÍæíáåã ( 5 ÃíÇã ãÞÇÈá 4 ÃíÇã). ÇáÔßá 5 ãÊæÓØ ãÏÉ ÇáÇÓÊÔÝÇÁ (ÈÇáÃíÇã) ÚäÏ ÇáãÑÖì ÇáãÊæÝíä ÅíÌÇÈíí ÇáÜ COVID-19 ÊÞÑíÑ ãÌãæÚÉ ãÑÇÞÈÉ COVID-19 ÈíÇäÇÊ ÇíØÇáíÇ ÈÊÇÑíÎ 20 ÂÐÇÑ 2020ã ÇáÔßá 5 ãÊæÓØ ãÏÉ ÇáÇÓÊÔÝÇÁ (ÈÇáÃíÇã) ÚäÏ ÇáãÑÖì ÇáãÊæÝíä ÅíÌÇÈíí ÇáÜ COVID-19 Çááæä ÇáÃÒÑÞ ãäÐ ÈÏÁ ÇáÃÚÑÇÖ æÍÊì ÇáæÝÇÉ Çááæä ÇáÃÍãÑ ÇáÝÇÊÍ ãäÐ ÈÏÁ ÇáÃÚÑÇÖ æÍäì ÇáÇÓÊÔÝÇÁ Çááæä ÇáÃÍãÑ ÇáÛÇãÞ ãäÐ ÇáÇÓÊÔÝÇÁ æÍÊì ÇáæÝÇÉ Çááæä ÇáÃÍãÑ ÇáãÎØØ ãäÐ ÇáÇÓÊÔÝÇÁ æÍÊì ÇáæÝÇÉ Ïæä ÚäÇíÉ ãÔÏÏÉ Çááæä ÇáÃÍãÑ ÇáãäÞØ ãäÐ ÇáÇÓÊÔÝÇÁ æÍÊì ÇáæÝÇÉ Ýí ÇáÚäÇíÉ ÇáãÔÏÏÉ 8.ÇáæÝíÇÊ ÊÍÊ ÚãÑ ÎãÓíä ÓäÉ Deaths under the age of 50 years To date (March the 20th), 36 of 3200 (1.1%) COVID-19 positive patients under the age of 50 have died. In particular, 9 of these were younger than 40 years, 8 men and 1 woman (age range between 31 and 39 years). For 2 patients under the age of 40 years, no clinical information is available; the remaining 7 had serious pre-existing pathologies (cardiovascular, renal, psychiatric pathologies, diabetes, obesity). ÍÊì ÊÇÑíÎ ÇáäÔÑ(20ÂÐÇÑ 2020ã) ÝÅäø 36 ãä ÃÕá 3200 Ãí 1¡1% ãä ÇáãÑÖì ÇáÅíÌÇÈíí ÇáÜ COVID-19 ÊÍÊ ÚãÑ ÇáÎãÓíä ÚÇãÇ ÊæÝæÇ æßÇä ÊÓÚÉ ãäåã ÊÍÊ ÚãÑ ÇáÜ 40 ÓäÉ¡ æáÇ íæÌÏ Íæáåã Ãí ãÚáæãÇÊ ÓÑíÑíÉ¡ ÃãÇ ÇáÓÈÚÉ ÇáÈÇÞæä ÝßÇäæÇ íÚÇäæä ãä ÃãÑÇÖ ÐÇÊ ÎØæÑÉ ÚÇáíÉ (ÃãÑÇÖ ÞáÈíÉ æÚÇÆíÉ¡ ßáæíÉ¡ äÝÓíÉ¡ ÓßÑí æÓãäÉ). ÇáãÕÏÑ : ÊÞÑíÑ ãÌãæÚÉ ãÑÇÞÈÉ æÈÇÁ ÇáßæÝíÏ 19- ÃíØÇáíÇ This report was produced by COVID-19 Surveillance Group Members of the COVID-19 Surveillance Group : ÇÚÖÇÁ ÇáãÌãæÚÉ Luigi Palmieri, Xanthi Andrianou, Antonino Bella, Stefania Bellino, Stefano Boros, Marco Canevelli, Maria Rita Castrucci, Alessandra Ciervo, Fortunato D'Ancona, Martina Del Manso, Chiara Donfrancesco, Massimo Fabiani, Antonietta Filia, Cinzia Lo Noce, Alberto Mateo Urdiales, Graziano Onder, Patrizio Pezzotti, Ornella Punzo, Valeria Raparelli, Giovanni Rezza, Flavia Riccardo, Maria Cristina Rota, Andrea Siddu, Paola Stefanelli, Brigid Unim, Nicola Vanacore, Silvio Brusaferro. 5 ãáÇÍÙÉ ãåãÉ ÇáÇÑÞÇã ÇáãÓÑæÏÉ ÇÚáÇå ÊÚØí ÊÝÇÕíá Úä Çæá 3200 ÍÇáÉ æÝÇÉ Çáíæã¡ 25/3/2020¡ ÈÓÇÚÉ äÔÑ åÐå ÇáãÚáæãÇÊ ÊÖÇÚÝ ÇáÑÞã¡ ææÕá Çáì 6800 ÍÇáÉ Ýí ÇíØÇáíÇ áæÍÏåÇ. æ Úáì ãÇ íÈÏæ¡ Çä ÝíÑæÓ ÇáßæÝíÏ 19 íÕÈÍ ÇßËÑ ÔÑÇÓÉ íæãÇ ÈÚÏ íæã. ÇÐÇ åÐå ÇáÇÑÞÇã ÞÇÈáÉ ááÊÈÏá ÇáÚÏÇÏ Çáíæãí áÍÇáÇÊ ÇáÇÕÇÈÉ æ ÇáæÝÇÉ ãä æÈÇÁ ÇáßæÝíÏ 19 – æÒÇÑÉ ÇáÕÍÉ ÇáÝÑäÓíÉ íæÖÍ åÐÇ ÇáÚÏÇÏ ÚÏÏ ÇáÇÕÇÈÇÊ ÇáãÓÌáÉ ÈÇáÚÇáã ÈÇæÑÈÇ æ ãäåÇ ÇíØÇáíÇ æ ÈÝÑäÓÇ æ Ëã ÚÏÏ ÇáæÝíÇÊ ãÞÇáÇÊ ÇÎÑì Íæá æÈÇÁ ÇáßæÝíÏ 19 ãä ÇÌá ÇáÇäÊÞÇá Çáì ÇáãæÇÖíÚ => æÈÇÁ ÇáßæÝíÏ 19 - ÇáßæÑæäÇ COVID 19 ßÇÑËÉ ÊåÏÏ ÇáÇäÓÇäíÉ ÇáÃÚÑÇÖ ÇáÔÚÇÚíÉ áãÑÖ ÇáßæÝíÏ 19 – æÈÇÁ ÇáßæÑæäÇ æÈÇÁ ÇáßæÝíÏ 19¡ ÇáßæÑæäÇ. ÇÍÕÇÆíÇÊ ÇæÑÈíÉ æ ÚÇáãíÉ covid 19 Corona virus ÎÕÇÆÕ ÇáãÑÖì ÇáÐíä ÊæÝæ ÈÓÈÈ æÈÇÁ ÇáßæÝíÏ 19 Ýí ÇíØÇáíÇ ßíÝ íÊßÇÑËÑ ÞíÑæÓ ÇáßæÑæäÇ ãÊáÇÒãÉ ÇáÔÑÞ ÇáÇæÓØ ÇáÊäÝÓíÉ ÇáãÑÊÈØÉ ÈÇáßæÑæäÇ ÝíÑæÓ 2012 æÈÇÁ ÇáÓÑÇÓ 2002 " ÚáÇÌ ÇáßæÑæäÇ ÈÇáßáæÑæßíä äÊíÌÉ ÏÑÇÓÉ ÇáÈÑæÝÓæÑ ÑÇÃæáÊ Úáì 80 ãÑíÖ " æÈÇÁ ÇáßæÝíÏ 19 ãÚØíÇÊ ÇÓÇÓíÉ æÊÇÑíÎíÉ ÇáÞÇÍ ÖÏ ÇáÓá åá íãßäå Çä íÓÈÈ æÞÇíÉ ãä æÈÇÁ ÇáßæÝíÏ 19 – ßæÑæäÇ _________________________ ÇÚÖÇÁ ãÌãæÚÉ ãÑÇÞÈÉ ÇáßæÝíÏ 19 Ýí ÇíØÇáíÇ Luigi Palmieri, Xanthi Andrianou, Antonino Bella, Stefania Bellino, Stefano Boros, Marco Canevelli, Maria Rita Castrucci, Alessandra Ciervo, Fortunato D'Ancona, Martina Del Manso, Chiara Donfrancesco, Massimo Fabiani, Antonietta Filia, Cinzia Lo Noce, Alberto Mateo Urdiales, Graziano Onder, Patrizio Pezzotti, Ornella Punzo, Valeria Raparelli, Giovanni Rezza, Flavia Riccardo, Maria Cristina Rota, Andrea Siddu, Paola Stefanelli, Brigid Unim, Nicola Vanacore, Silvio Brusaferro. 5 ÝåÑÓ ÇáãÞÇáÇÊ ÇáãäÔæÑÉ Úáì ãæÞÚ ØÈíÈ ÇáæÈ Úä ÇáßæÑæäÇ – æÈÇÁ ÇáßæÝíÏ 19
25/3/2020
2014
http://tabib-web.eu - http://www.tabib-web.eu
